Literature DB >> 25887610

Detecting latent tuberculosis in compromised patients.

Ilaria Sauzullo1, Vincenzo Vullo, Claudio M Mastroianni.   

Abstract

PURPOSE OF REVIEW: The detection of latent tuberculosis infection (LTBI) in different categories of compromised patients is reviewed with focus on the role of strategies incorporating immunodiagnostic tests and analysis of epidemiological and clinical risk factors. RECENT
FINDINGS: The development of active tuberculosis (TB) is increased in compromised patients and is closely related to determinants for disease reactivation or newly acquired TB infection. A targeted detection of LTBI in these high-risk groups should be performed especially if preventive treatment is planned. The performance of immunodiagnostic tests is highly variable among different groups of immunocompromised individuals. Findings of cross-sectional studies indicate a better diagnostic accuracy of interferon-γ release assays over the tuberculin skin test. The critical issue is that in low-incidence countries, the positive and negative predictive values of any of immunodiagnostic tests were very poor. A targeted testing process involving analysis of TB risk factors increases the predictive positive values of immunodiagnostic tests and may improve LTBI detection.
SUMMARY: The LTBI detection in immunocompromised patients is a challenge. The development of new immunological biomarkers and integrated clinical and epidemiological strategies are needed to identify LTBI in compromised individuals and to plan preventive chemotherapies in those at risk of developing active TB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25887610     DOI: 10.1097/QCO.0000000000000158

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  6 in total

1.  A Mycobacterium tuberculosis Dormancy Antigen Differentiates Latently Infected Bacillus Calmette-Guérin-vaccinated Individuals.

Authors:  Delfina Peña; Ana I Rovetta; Rodrigo E Hernández Del Pino; Nicolás O Amiano; Virginia Pasquinelli; Joaquín M Pellegrini; Nancy L Tateosian; Agustín Rolandelli; Marisa Gutierrez; Rosa M Musella; Domingo J Palmero; María M Gherardi; Juan Iovanna; H Eduardo Chuluyan; Verónica E García
Journal:  EBioMedicine       Date:  2015-05-30       Impact factor: 8.143

2.  Infectious risk stratification in multiple sclerosis patients receiving immunotherapy.

Authors:  Jonas Graf; Verena I Leussink; Thomas Dehmel; Marius Ringelstein; Norbert Goebels; Ortwin Adams; Colin R MacKenzie; Clemens Warnke; Torsten Feldt; Anna Lammerskitten; Luisa Klotz; Sven Meuth; Heinz Wiendl; Hans-Peter Hartung; Orhan Aktas; Philipp Albrecht
Journal:  Ann Clin Transl Neurol       Date:  2017-11-24       Impact factor: 4.511

3.  Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics.

Authors:  Shetty Ravi Dyavar; Timothy M Mykris; Lee C Winchester; Kimberly K Scarsi; Courtney V Fletcher; Anthony T Podany
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

4.  Screening for Latent Tuberculosis Infection in Patients with Autoimmune Diseases Before Initiating TNF-α Inhibitors Therapy.

Authors:  Dimitra Perifanou; Daniil Zoe; Efthimia Petinaki; Konstantinos Konstantinou; Konstantinos Gourgoulianis
Journal:  Mater Sociomed       Date:  2018-03

5.  HIV-Infected Patients Developing Tuberculosis Disease Show Early Changes in the Immune Response to Novel Mycobacterium tuberculosis Antigens.

Authors:  Noemi Rebecca Meier; Manuel Battegay; Tom H M Ottenhoff; Hansjakob Furrer; Johannes Nemeth; Nicole Ritz
Journal:  Front Immunol       Date:  2021-03-12       Impact factor: 7.561

6.  Heme oxygenase-1 and neopterin plasma/serum levels and their role in diagnosing active and latent TB among HIV/TB co-infected patients: a cross sectional study.

Authors:  Esther Uwimaana; Bernard S Bagaya; Barbara Castelnuovo; David P Kateete; Anguzu Godwin; Noah Kiwanuka; Christopher C Whalen; Moses L Joloba
Journal:  BMC Infect Dis       Date:  2021-07-27       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.